Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREEDOM
2024-510981-18-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall response rate after six cycles of salvage therapy. Planned start Jul 2024; status: authorised.
02
Drugs
dexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-510981-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510981-18-00.